Literature DB >> 12460235

Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura.

Minori Nagahama1, Shosaku Nomura, Shigenori Kanazawa, Yoshio Ozaki, Hideo Kagawa, Shirou Fukuhara.   

Abstract

We investigated the levels of various chemokines and soluble CD40L (sCD40L) in ITP patients, in order to determine the influence of CD40-CD40L interaction on the pathogenesis of ITP. We found increases in MCP-1 and RANTES levels in ITP patients compared with those in healthy individuals. Thirty-eight of the 65 ITP patients (58.5%) had elevated levels of sCD40L. We found significant decreases in platelet counts in sCD40L-positive ITP patients. Although the sCD40L level did not differ significantly between the control and nonimmune thrombocytopenia groups, but among ITP patients. sCD40L level was significantly higher in those with untreated ITP than in those with treated ITP. In addition, significant increases in RANTES, MCP-1, sCD14, and sP-selectin levels were observed in sCD40L-positive ITP patients, although sE-selectin levels were not increased in such patients. For other factors examined, however, there were no differences in level between sCD40L-positive and -negative ITP patients. These findings suggests that there are two groups of ITP patients, one with elevated and one with normal of sCD40L. ITP cases in which sCD40L was increased appeared to involve changes in platelet counts and monocyte activation. The pathogenesis of ITP may in some patients include alterations of the CD40/CD40L pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460235     DOI: 10.1034/j.1600-0609.2002.02774.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  9 in total

1.  Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation.

Authors:  Lucia Sereni; Maria Carmina Castiello; Francesco Marangoni; Achille Anselmo; Dario di Silvestre; Sara Motta; Elena Draghici; Stefano Mantero; Adrian J Thrasher; Silvia Giliani; Alessandro Aiuti; Pierluigi Mauri; Luigi D Notarangelo; Marita Bosticardo; Anna Villa
Journal:  J Allergy Clin Immunol       Date:  2018-02-06       Impact factor: 10.793

2.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Authors:  Weili Bao; James B Bussel; Susanne Heck; Wu He; Marissa Karpoff; Nayla Boulad; Karina Yazdanbakhsh
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

3.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

4.  Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE.

Authors:  Piotr Piotrowski; Margarita Lianeri; Robert Gasik; Andrzej Roszak; Marzena Olesińska; Paweł P Jagodziński
Journal:  J Biomed Biotechnol       Date:  2010-04-21

Review 5.  Future innovations in anti-platelet therapies.

Authors:  N E Barrett; L Holbrook; S Jones; W J Kaiser; L A Moraes; R Rana; T Sage; R G Stanley; K L Tucker; B Wright; J M Gibbins
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

6.  Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain.

Authors:  María-Eva Mingot-Castellano; Carlos Grande-García; David Valcárcel-Ferreiras; Clara Conill-Cortés; Loreto de Olivar-Oliver
Journal:  Case Rep Hematol       Date:  2017-06-11

Review 7.  Platelets in ITP: Victims in Charge of Their Own Fate?

Authors:  Vivianne S Nelson; Anne-Tess C Jolink; Sufia N Amini; Jaap Jan Zwaginga; Tanja Netelenbos; John W Semple; Leendert Porcelijn; Masja de Haas; Martin R Schipperus; Rick Kapur
Journal:  Cells       Date:  2021-11-19       Impact factor: 6.600

Review 8.  Pathobiology of secondary immune thrombocytopenia.

Authors:  Douglas B Cines; Howard Liebman; Roberto Stasi
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

9.  Cytokine changes during treatment of anti-Caspr2 encephalitis: a case report.

Authors:  Yi-Chia Wei; Chia-Lun Wu; Wei-Chieh Weng
Journal:  BMC Neurol       Date:  2020-08-13       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.